Parkin-mediated ubiquitination regulates phospholipase C-γ1
Nodi Dehvari
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
These authors have contributed equally.
Search for more papers by this authorAnna Sandebring
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
Laboratory of Neurogenetics, National Institute on Aging/NIH, Bethesda, MD, USA
These authors have contributed equally.
Search for more papers by this authorAmilcar Flores-Morales
Karolinska Institutet, Center of Molecular Medicine, Stockholm, Sweden
Search for more papers by this authorLaura Mateos
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
Search for more papers by this authorYin-Choy Chuan
Karolinska Institutet, Center of Molecular Medicine, Stockholm, Sweden
Search for more papers by this authorMatthew S. Goldberg
Departments of Neurology and Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA
Search for more papers by this authorMark R. Cookson
Laboratory of Neurogenetics, National Institute on Aging/NIH, Bethesda, MD, USA
Search for more papers by this authorRichard F. Cowburn
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
AstraZeneca R&D, Local Discovery RA CNS & Pain Control, Disease Biology, Södertälje, Sweden
Search for more papers by this authorCorresponding Author
Angel Cedazo-Mínguez
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
Correspondence to: Angel CEDAZO-MÍNGUEZ, Karolinska Institutet, Department of NVS,KI-Alzheimer’s Disease Research Center, NOVUM floor. 5. 141 57 Stockholm, Sweden.Tel.: +46 858 583 880E-mail: [email protected]Search for more papers by this authorNodi Dehvari
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
These authors have contributed equally.
Search for more papers by this authorAnna Sandebring
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
Laboratory of Neurogenetics, National Institute on Aging/NIH, Bethesda, MD, USA
These authors have contributed equally.
Search for more papers by this authorAmilcar Flores-Morales
Karolinska Institutet, Center of Molecular Medicine, Stockholm, Sweden
Search for more papers by this authorLaura Mateos
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
Search for more papers by this authorYin-Choy Chuan
Karolinska Institutet, Center of Molecular Medicine, Stockholm, Sweden
Search for more papers by this authorMatthew S. Goldberg
Departments of Neurology and Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA
Search for more papers by this authorMark R. Cookson
Laboratory of Neurogenetics, National Institute on Aging/NIH, Bethesda, MD, USA
Search for more papers by this authorRichard F. Cowburn
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
AstraZeneca R&D, Local Discovery RA CNS & Pain Control, Disease Biology, Södertälje, Sweden
Search for more papers by this authorCorresponding Author
Angel Cedazo-Mínguez
Karolinska Institutet, Department of NVS, KI-Alzheimer’s Disease Research Center, Stockholm, Sweden
Correspondence to: Angel CEDAZO-MÍNGUEZ, Karolinska Institutet, Department of NVS,KI-Alzheimer’s Disease Research Center, NOVUM floor. 5. 141 57 Stockholm, Sweden.Tel.: +46 858 583 880E-mail: [email protected]Search for more papers by this authorAbstract
Mutations in parkin cause autosomal recessive forms of Parkinson’s disease (PD), with an early age of onset and similar pathological phenotype to the idiopathic disease. Parkin has been identified as an E3 ubiquitin ligase that mediates different types of ubiquitination, which has made the search for substrates an intriguing possibility to identify pathological mechanisms linked to PD. In this study, we present PLCγ1 as a novel substrate for parkin. This association was found in non-transfected human neuroblastoma SH-SY5Y cells as well as in stable cell lines expressing parkin WT and familial mutants R42P and G328E. Analysis of cortical, striatal and nigral human brain homogenates revealed that the interaction between parkin and PLCγ1 is consistent throughout these regions, suggesting that the interaction is likely to have a physiological relevance for humans. Unlike many of the previously identified substrates, we could also show that the steady-state levels of PLCγ1 is significantly higher in parkin KO mice and lower in parkin WT human neuroblastoma cells, suggesting that parkin ubiquitination of PLCγ1 is required for proteasomal degradation. In line with this idea, we show that the ability to ubiquitinate PLCγ1 in vitro differs significantly between WT and familial mutant parkin. In this study, we demonstrate that parkin interacts with PLCγ1, affecting PLCγ1 steady state protein levels in human and murine models with manipulated parkin function and expression levels. This finding could be of relevance for finding novel pathogenic mechanisms leading to PD.
Supporting Information
Figure S1. Parkin does not interact with protein kinase C-ϵ (PKC-ϵ). To ensure the specificity of the parkin/PLC-γ1 interaction, (A) lysates from stably transfected human SH-SY5Y neuroblastoma cells with wild-type parkin (WT) were immunoprecipitated with either anti-PKC-ϵ or anti-PLC-γ1 antibodies and detected by Western blotting with anti-PKC-ϵ, anti-PLC-γ1 or anti-parkin antibodies. (B) Confocal micrograph of parkin WT cells double stained with with anti-parkin (red) and anti-PKCϵ (green) antibodies. Neither association nor colocalization between parkin and PKCϵ was found.
indent="no">Please note: Blackwell Publishing are not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
Filename | Description |
---|---|
JCMM_443_sm_fS1.pdf2.5 MB | Supporting info item |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1 Forno LS, DeLanney LE, Irwin I, et al . Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. Adv Neurol. 1996; 69: 217–28.
- 2 Chua CE, Tang BL. Alpha-synuclein and Parkinson’s disease: the first roadblock. J Cell Mol Med. 2006; 10: 837–46.
- 3 Hardy J, Cai H, Cookson MR, et al . Genetics of Parkinson’s disease and parkinsonism. Ann Neurol. 2006; 60: 389–98.
- 4 Kitada T, Asakawa S, Hattori N, et al . Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998; 392: 605–8.
- 5 Shimura H, Hattori N, Kubo S, et al . Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet. 2000; 25: 302–5.
- 6 Moore DJ, West AB, Dikeman DA, et al . Parkin mediates the degradation-independent ubiquitination of Hsp70. J Neurochem. 2008; 105: 1806–19.
- 7 Morett E, Bork P. A novel transactivation domain in parkin. Trends Biochem Sci. 1999; 24: 229–31.
- 8 Sakata E, Yamaguchi Y, Kurimoto E, et al . Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 2003; 4: 301–6.
- 9 Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem. 2000; 275: 35661–4.
- 10 Staropoli JF, McDermott C, Martinat C, et al . Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron. 2003; 37: 735–49.
- 11 Corti O, Hampe C, Koutnikova H, et al . The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet. 2003; 12: 1427–37.
- 12 Shimura H, Schlossmacher MG, Hattori N, et al . Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science. 2001; 293: 263–9.
- 13 Imai Y, Soda M, Inoue H, et al . An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001; 105: 891–902.
- 14 Huynh DP, Scoles DR, Nguyen D, et al . The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum Mol Genet. 2003; 12: 2587–97.
- 15 Zhang Y, Gao J, Chung KK, et al . Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA. 2000; 97: 13354–9.
- 16 Ko HS, Kim SW, Sriram SR, et al . Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem. 2006; 281: 16193–6.
- 17 Fallon L, Belanger CM, Corera AT, et al . A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat Cell Biol. 2006; 8: 834–42.
- 18 Joch M, Ase AR, Chen CX, et al . Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol Biol Cell. 2007; 18: 3105–18.
- 19 Ko HS, von Coelln R, Sriram SR, et al . Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci. 2005; 25: 7968–78.
- 20 Choi P, Snyder H, Petrucelli L, et al . SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res. 2003; 117: 179–89.
- 21 Wang Y, Wu J, Wang Z. Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol Biol Cell. 2006; 17: 2267–77.
- 22 Tvorogov D, Carpenter G. EGF-dependent association of phospholipase C-gamma1 with c-Cbl. Exp Cell Res. 2002; 277: 86–94.
- 23 Goldberg MS, Fleming SM, Palacino JJ, et al . Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem. 2003; 278: 43628–35.
- 24 Cookson MR, Lockhart PJ, McLendon C, et al . RING finger 1 mutations in Parkin produce altered localization of the protein. Hum Mol Genet. 2003; 12: 2957–65.
- 25 Rhee SG, Bae YS. Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem. 1997; 272: 15045–8.
- 26 Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem. 2001; 70: 281–312.
- 27 Song C, Hu CD, Masago M, et al . Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras. J Biol Chem. 2001; 276: 2752–7.
- 28 Saunders CM, Larman MG, Parrington J, et al . PLC zeta: a sperm-specific trigger of Ca(2+) oscillations in eggs and embryo development. Development. 2002; 129: 3533–44.
- 29 Hwang JI, Oh YS, Shin KJ, et al . Molecular cloning and characterization of a novel phospholipase C, PLC-eta. Biochem J. 2005; 389: 181–6.
- 30 Carpenter G, Ji Q. Phospholipase C-gamma as a signal-transducing element. Exp Cell Res. 1999; 253: 15–24.
- 31 Toker A. Signaling through protein kinase C. Front Biosci. 1998; 3: D1134–47.
- 32 Munaron L, Antoniotti S, Lovisolo D. Intracellular calcium signals and control of cell proliferation: how many mechanisms? J Cell Mol Med. 2004; 8: 161–8.
- 33 Verkhratsky A, Toescu EC. Neuronal-glial networks as substrate for CNS integration. J Cell Mol Med. 2006; 10: 826–36.
- 34 Hirsch EC, Faucheux B, Damier P, et al . Neuronal vulnerability in Parkinson’s disease. J Neural Transm Suppl. 1997; 50: 79–88.
- 35 Mouatt-Prigent A, Karlsson JO, Agid Y, et al . Increased M-calpain expression in the mesencephalon of patients with Parkinson’s disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience. 1996; 73: 979–87.